On September 17, 2019 Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA,OTCQB: MDNAF), a clinical stage immuno-oncology company, reported that it will present an update on the lead candidate from its IL-2 superkine platform, MDNA19, at the International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper) to be held from September 25-28, 2019 in Paris, France (Press release, Medicenna Therapeutics, SEP 17, 2019, View Source [SID1234539600]). The conference is co-sponsored by the Cancer Research Institute (CRI), the Association for Cancer Immunotherapy (CIMT) (Free CIMT Whitepaper), the European Academy of Tumor Immunology (EATI), and the American Association for Cancer Research (AACR) (Free AACR Whitepaper).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will provide additional preclinical data on MDNA19 (formally known as MDNA109-LA1), a best-in-class long-acting IL-2 developed from Medicenna’s Superkine platform that has shown unique ability to selectively stimulate cancer killing immune cells without the limitations seen with other long-acting IL-2 programs.

The details of the poster presentation are as follows:

Title:

Long-acting MDNA109: Emerging IL-2 Superkines displaying potent anti-tumoral responses.

Presenter:

Dr. Minh To, Ph.D.

Poster #:

B042

Date/Time:

Friday, September 27th, 2019 from 1:00-3:00pm and 6:30-8:00pm

Location:

Espace Grande Arche, Tunnel de Nanterre-La Défense, 92044 Paris La Défense, France